Zobrazeno 1 - 10
of 45
pro vyhledávání: '"C Huang-Bartlett"'
Autor:
Eric Gauthier, DJ Slamon, F Andre, Massimo Cristofanilli, C Huang Bartlett, Zhe Zhang, N. Turner, Sherene Loi, S. Loibl, Richard S. Finn, AM DeMichele, HS Rugo, Karen A. Gelmon, Yuan Liu, Véronique Diéras, Carla Giorgetti
Publikováno v:
Cancer Research. 79:P6-18
Background: Palbociclib (PAL) in combination with endocrine therapy (ET) is a preferred treatment option for untreated and previously treated patients with hormone receptor–positive (HR+), human epidermal growth factor receptor 2 (HER2)–negative
Autor:
Isabel Alvarez, Miguel Gil-Gil, C Huang Bartlett, Montse Muñoz, Christiane Thallinger, J. de la Haba-Rodríguez, E. Alba, Xin-Yun Huang, A. García-Palomo, Manuel Ramos, Manuel Ruiz-Borrego, Christoph C. Zielinski, Serafin Morales, Jose Ignacio Chacon, Angel Guerrero-Zotano, Tibor Csoszi, M Casas, Eva Carrasco, Mireia Margeli, Massimo Corsaro, Begoña Bermejo, Maria Koehler, Nicholas C. Turner, Antonio Antón, Eva Ciruelos, Lourdes Calvo, Rosalia Caballero, José A. García-Sáenz, L. Murillo, Zsuzsanna Kahán, Einav Nili Gal-Yam, Claire Swift, Miguel Martin
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Annals of Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Annals of oncology : official journal of the European Society for Medical Oncology
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
Zaguán: Repositorio Digital de la Universidad de Zaragoza
Universidad de Zaragoza
Universidad de Barcelona
Annals of Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Annals of oncology : official journal of the European Society for Medical Oncology
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
Zaguán: Repositorio Digital de la Universidad de Zaragoza
Universidad de Zaragoza
BACKGROUND: Palbociclib plus endocrine therapy (ET) is the standard treatment for hormone receptor-positive and human epidermal growth factor receptor 2-negative, metastatic breast cancer (MBC). However, its efficacy has not been compared with that o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51f6348ffb7d8ef8463236763e5a9d56
http://hdl.handle.net/2445/176002
http://hdl.handle.net/2445/176002
Autor:
Jack Mardekian, M Fahed Rimawi, Maria Koehler, C Huang Bartlett, Erica L. Mayer, HJ Burstein, Lynn McRoy, J Harnett, AM DeMichele
Publikováno v:
Cancer Research. 78:P3-11
Background: NCCN guidelines recommend that premenopausal women with HR+/HER2- metastatic breast cancer (MBC) be rendered postmenopausal and then treated accordingly. After its approval in February 2015, the CDK4/6 inhibitor palbociclib (P), in combin
Autor:
Ke Zhang, Noriyuki Masuda, S. Verma, N. Turner, S. L. Moulder, C Huang-Bartlett, DJ Slamon, W Sun, Richard S. Finn, S Kim, HS Rugo, Nadia Harbeck, Anil A. Joy, Patrick Schnell, Y-H Im
Publikováno v:
Cancer Research. 77:P4-22
Background: At least 40% of breast cancers are diagnosed in women ≥65 y old and most are hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-). Palbociclib (PAL) is an oral, small-molecule inhibitor of cyclin-depen
Autor:
Massimo Cristofanilli, S. Verma, Marco Colleoni, H. Iwata, DJ Slamon, Nadia Harbeck, Jungsil Ro, Fabrice Andre, C Huang Bartlett, Ke Zhang, Sherene Loi, N. Turner, Carla Giorgetti
Publikováno v:
Cancer Research. 77:P4-22
Background: Palbociclib (PAL) plus fulvestrant (FUL) demonstrated significant improvement in progression-free survival (PFS) vs placebo (PBO) plus FUL in women with HR+/HER2- advanced breast cancer (ABC) whose disease had progressed on prior endocrin
Autor:
Georg Pfeiler, Erica L. Mayer, William H. Barry, Otto Metzger, Antonio C. Wolff, P Rastogi, M.J. Piccart, HJ Burstein, Dimitrios Zardavas, Xin-Yun Huang, C Huang-Bartlett, S. Loibl, Maria Koehler, Christian Fesl, Theodora Goulioti, EP Winer, M. Gnant, Katherine E. Miller, AM DeMichele
Publikováno v:
Cancer Research. 78:OT3-05
Background: Cell cycle inhibition is a proven target for novel cancer therapeutics. Palbociclib (P) is an orally active inhibitor of CDK4/6, and arrests the cell cycle at the G1-S transition. P in combination with endocrine therapy (ET) has demonstra
Autor:
Maria Koehler, Angela DeMichele, William T. Barry, Rinath Jeselsohn, Beth Overmoyer, EP Winer, Adrienne G. Waks, Kathy D. Miller, Harold J. Burstein, Hope S. Rugo, C Huang Bartlett, Therese M. Mulvey, H Guo, Erica L. Mayer, Steven E. Come
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 30(9)
Background The CDK4/6 inhibitor palbociclib prolongs progression-free survival in hormone receptor-positive/HER2-negative (HR+/HER2−) metastatic breast cancer when combined with endocrine therapy. This phase II trial was designed to determine the f
Autor:
Hope S. Rugo, Nadia Harbeck, Karen A. Gelmon, Oleg Lipatov, Richard S. Finn, Véronique Diéras, Anil Abraham Joy, Shrividya Iyer, Aurelio Castrellon, C Huang Bartlett, Johannes Ettl, Eric Gauthier, D. Lu, DJ Slamon, A. Mori
Publikováno v:
Breast cancer research and treatment, vol 174, iss 3
Breast Cancer Research and Treatment
Breast Cancer Research and Treatment
Purpose In the initial PALOMA-2 (NCT01740427) analysis with median follow-up of 23 months, palbociclib plus letrozole significantly prolonged progression-free survival (PFS) in women with estrogen receptor-positive (ER+)/human epidermal growth factor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6086ade4bfade3a571815d3e6444f35b
https://escholarship.org/uc/item/2vh1n834
https://escholarship.org/uc/item/2vh1n834
Autor:
Massimo Cristofanilli, Nadia Harbeck, Jungsil Ro, A Thiele, Nicholas C. Turner, H. Iwata, H Rugo, AM DeMichele, C Huang Bartlett, Marco Colleoni, Sherene Loi, Patrick Schnell, Sunil Verma, Vered Stearns, Ke Zhang
Publikováno v:
Cancer Research. 76:P4-13
Background: Endocrine therapy (ET) resistance remains a major clinical problem for patients (pts) with hormone receptor (HR+) breast cancer (BC). In PALOMA-3, palbociclib (P) combined with fulvestrant (F) demonstrated significant prolongation of prog
Autor:
Johannes Ettl, C Huang Bartlett, Yaroslav Shparyk, Ravindranath Patel, S.-B. Kim, Tamás Pintér, Xin-Yun Huang, DJ Slamon, Sophia Randolph, J.P. Crown, Richard S. Finn, Anu Thummala, Sashi Nadanaciva
Publikováno v:
Cancer Research. 76:P4-13
Background Palbociclib (P) is an oral CDK4/6 inhibitor. In PALOMA-1/TRIO-18, a randomized phase 2 trial, addition of P to letrozole (L) significantly prolonged progression-free survival (PFS) (20 mo with P+L vs 10 mo with L alone; HR = 0.488, P=0.000